Cybin Inc Ordinary Shares CYBN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CYBN is a good fit for your portfolio.
News
-
Cybin to Participate at the 27th Annual Milken Institute Global Conference
-
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
-
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million
-
Thinking about buying stock in Aquestive Therapeutics, Spruce Biosciences, Vale, Marathon Digital Holdings, or Cybin?
-
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
-
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
Trading Information
- Previous Close Price
- $0.35
- Day Range
- $0.34–0.35
- 52-Week Range
- $0.22–0.74
- Bid/Ask
- $0.34 / $0.34
- Market Cap
- $259.98 Mil
- Volume/Avg
- 671,321 / 5.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various psychiatric and neurological conditions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 50
- Website
- https://www.cybin.com
Comparables
Valuation
|
Metric
|
CYBN
|
BLU
|
AUPH
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.76 | 5.83 | 1.91 |
Price/Sales | — | — | 4.09 |
Price/Cash Flow | — | — | — |
Price/Earnings
CYBN
BLU
AUPH
Financial Strength
|
Metric
|
CYBN
|
BLU
|
AUPH
|
|---|---|---|---|
Quick Ratio | 5.11 | 32.13 | 4.85 |
Current Ratio | 5.76 | 33.42 | 5.50 |
Interest Coverage | −17,681.75 | −1,125.80 | −33.04 |
Quick Ratio
CYBN
BLU
AUPH
Profitability
|
Metric
|
CYBN
|
BLU
|
AUPH
|
|---|---|---|---|
Return on Assets (Normalized) | −78.75% | −21.75% | −7.67% |
Return on Equity (Normalized) | −326.34% | −26.24% | −10.09% |
Return on Invested Capital (Normalized) | −87.56% | −24.47% | −11.04% |
Return on Assets
CYBN
BLU
AUPH
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zdrbctzdfn | Wmtjv | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gytbgjr | Dhxfmhd | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fgqwvddm | Wwchfd | $98.3 Bil | |
MRNA
| Moderna Inc | Lzgntrpp | Dfjf | $42.7 Bil | |
ARGX
| argenx SE ADR | Ssrslzvnv | Qqyh | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Nrhmjklc | Twpsg | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Twvbfwnt | Wmnmd | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vrsbjrjd | Rxlqfq | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tnqhrcgxg | Ygbcht | $12.7 Bil | |
INCY
| Incyte Corp | Ywffzmj | Dwyfjt | $11.8 Bil |